Clinical Trial
Study Details
Enrollment
26
Interventions
Description
Oral, daily for 12 days
Name
Prasugrel
Type
Drug
Phase
Phase 1
Status
COMPLETED
Study ID #
NCT01178099
Study Type
Interventional
Summary
The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).
Study Overview
Conditions
Contacts and Locations
Locations
Facility
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
London
UK
SE 1 1YR
United Kingdom
GeoPoint
51.50853, -0.12574